<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01868880</url>
  </required_header>
  <id_info>
    <org_study_id>calo03</org_study_id>
    <secondary_id>calo03</secondary_id>
    <nct_id>NCT01868880</nct_id>
  </id_info>
  <brief_title>Effect of Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Right Ventricular Pacing</brief_title>
  <official_title>Effect of Heart Rate Control Using Ivabradine and Beta-blockers Combination Versus Beta-blockers Up-titration on Ventricular Pacing in Heart Failure Patients With an Implanted Cardioverter Defibrillator.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinico Casilino ASL RMB</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Policlinico Casilino ASL RMB</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized and controlled trial is to evaluate the use of the&#xD;
      ivabradine in combination to a low-dose of beta-blocker (bisoprolol) versus up-titration of&#xD;
      beta-blocker (bisoprolol) to obtain heart rate (HR) control with reduction in RV pacing in&#xD;
      single-chamber or dual chambers ICD recipients HF patients with moderate to severe left&#xD;
      ventricular dysfunction (FE ≤ 40%) and an heart rate ≥ 70 bpm in sinus rhythm over a&#xD;
      12-months follow up.&#xD;
&#xD;
      Besides the investigators want to assess if the combination of ivabradine to a low-dose of&#xD;
      beta-blocker (bisoprolol) versus up-titration of beta-blocker (bisoprolol) may determine a&#xD;
      lower degree of left ventricular dysfunction progression, the reduction of ventricular&#xD;
      arrhythmias burden and ICD appropriate therapy occurrence and the improvement of quality of&#xD;
      life in ICD heart failure patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background&#xD;
&#xD;
      High heart rate (HR) represent per se a risk factor for cardiovascular mortality and heart&#xD;
      failure (HF) progression, despite optimal HF therapy. Beta-blockers remain the therapy of&#xD;
      choice in all patients with systolic HF, but they may worsen atrioventricular (AV) conduction&#xD;
      and increase right ventricular (RV) pacing percentage. Several studies have demonstrated&#xD;
      detrimental effects of RV pacing on cardiac function. Percent RV pacing &gt; 40-50% is an&#xD;
      independent predictor of death and hospitalization for HF in implantable&#xD;
      cardioverter-defibrillator(ICD) patients, particularly in those with preexistent left&#xD;
      ventricular dysfunction.1,2 Cumulative RV pacing &gt; 2% and ejection fraction (EF) &lt; 40% are&#xD;
      independent predictors for Ventricular Tachycardia(VT)/Ventricular Fibrillation (VF)&#xD;
      occurrence in ICD patients.3 Therefore reduction of cumulative RV pacing as far as possible&#xD;
      should be achieved in ICD patients. Ivabradine is a specific inhibitor of the If current of&#xD;
      the sinus node, that induces a selective and dose dependent HR reduction; it is a pure HR&#xD;
      lowering agent without effects on AV conduction or contractility.4 In HF patients implanted&#xD;
      with an ICD ivabradine could act as an heart rate control drug in combination with a&#xD;
      beta-blocker without increase right ventricular (RV) pacing percentage and may be an option&#xD;
      to reduce left-ventricular dysfunction progression and ventricular arrhythmias burden and&#xD;
      appropriate ICD therapy.&#xD;
&#xD;
      Aim&#xD;
&#xD;
      The aim of this prospective, randomized and controlled trial is to evaluate the use of the&#xD;
      ivabradine in combination to a low-dose of beta-blocker (bisoprolol) versus up-titration of&#xD;
      beta-blocker (bisoprolol) to obtain heart rate (HR) control with reduction in RV pacing in&#xD;
      single-chamber or dual chambers ICD recipients HF patients with moderate to severe left&#xD;
      ventricular dysfunction (FE ≤ 40%) and an heart rate ≥70 bpm in sinus rhythm over a 12-months&#xD;
      follow up.&#xD;
&#xD;
      Besides we want to assess if the combination of ivabradine to a low-dose of beta-blocker&#xD;
      (bisoprolol) versus titration of beta-blocker (bisoprolol) may determine a lower degree of&#xD;
      left ventricular dysfunction progression, the reduction of ventricular arrhythmias burden and&#xD;
      ICD appropriate therapy occurrence and the improvement of quality of life in ICD heart&#xD;
      failure patients.&#xD;
&#xD;
      Endpoints of the study&#xD;
&#xD;
      Primary endpoints:&#xD;
&#xD;
      Right ventricular pacing percentage increase &gt; 50% or Cardiovascular death or Heart failure&#xD;
      decompensation or Crossover due to worsening heart failure.&#xD;
&#xD;
      Secondary endpoints:&#xD;
&#xD;
      Ejection fraction decrease &lt; 5% and Left Ventricular End-Systolic Volume decrease &lt;15%.&#xD;
&#xD;
      Ventricular arrhythmias and ICD appropriate therapy reduction. Heart rate variability&#xD;
      improvement NYHA Classification improvement Minnesota Living With Heart Failure Questionnaire&#xD;
      (MLHFQ) total score reduction.&#xD;
&#xD;
      Right ventricular pacing percentage. Composite endpoint: cardiovascular death and&#xD;
      hospitalization due to worsening heart failure.&#xD;
&#xD;
      Crossover rate due to worsening heart failure&#xD;
&#xD;
      Study protocol:&#xD;
&#xD;
      Baseline assessment:&#xD;
&#xD;
      Clinical visit: demographic data, risk factors for cardiovascular disease, primary cause of&#xD;
      heart failure, NYHA class, comorbidities, echocardiographic parameters, drug therapy,&#xD;
      cardiovascular hospitalizations in the last year.&#xD;
&#xD;
      Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced&#xD;
      rhythm, QRS duration); Blood pressure measurement; Electronic device control (for assessment&#xD;
      of right ventricular stimulation percentage; electrical parameters and arrhythmias diagnostic&#xD;
      data); Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic&#xD;
      volumes, left ventricular ejection fraction); MLHFQ&#xD;
&#xD;
      Assignment of consecutive patients to treatment with ivabradine plus beta-blocker(bisoprolol)&#xD;
      or beta-blocker (bisoprolol) titration. Mean Heart Rate Target is 55-70 bpm for both groups.&#xD;
&#xD;
      Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of&#xD;
      beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be&#xD;
      eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes,&#xD;
      diplopia, headache or dizziness).&#xD;
&#xD;
      Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of&#xD;
      1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.&#xD;
&#xD;
      Patients are controlled in office follow-up visits after 3, 6 and 12 months, in addition to a&#xD;
      Remote Monitoring program for clinical data and trend reviewing at least every 15 days or as&#xD;
      soon as possible whenever a Remote Monitoring alert notification is received. Besides every&#xD;
      15 days patients will receive a telephone contact in order to evaluate their clinical state&#xD;
      and to uptitrate the beta blocker therapy based on mean heart rate detected trough remote&#xD;
      control of the ICD.&#xD;
&#xD;
      Three months in-office follow-up:&#xD;
&#xD;
      Clinical visit: symptoms, NYHA class, drug therapy, cardiovascular hospitalizations in the&#xD;
      last three months.&#xD;
&#xD;
      Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced&#xD;
      rhythm, QRS duration); Blood pressure measurement; Echocardiogram (for assessment of left&#xD;
      ventricular end-diastolic and end-systolic volumes, left ventricular ejection fraction);&#xD;
      Electronic device control (for assessment of right ventricular stimulation percentage;&#xD;
      electrical parameters and arrhythmias diagnostic data) .&#xD;
&#xD;
      Six months in office follow-up:&#xD;
&#xD;
      Clinical visit: NYHA class, comorbidities, echocardiographic parameters, drug therapy,&#xD;
      cardiovascular hospitalizations in the last three months.&#xD;
&#xD;
      Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced&#xD;
      rhythm, QRS duration); Echocardiogram (for assessment of left ventricular end-diastolic and&#xD;
      end-systolic volumes, left ventricular ejection fraction); Electronic device control (for&#xD;
      assessment of right ventricular stimulation percentage; electrical parameters and arrhythmias&#xD;
      diagnostic data).&#xD;
&#xD;
      MLHFQ&#xD;
&#xD;
      One year in office follow-up:&#xD;
&#xD;
      Clinical visit: NYHA class, comorbidities, echocardiographic parameters, drug therapy,&#xD;
      cardiovascular hospitalizations in the last three months.&#xD;
&#xD;
      Rest ECG (for assessment of rest heart rate, presence of sinus rhythm or device-induced&#xD;
      rhythm, QRS duration); Electronic device control (for assessment of right ventricular&#xD;
      stimulation percentage; electrical parameters and arrhythmias diagnostic data).&#xD;
&#xD;
      Echocardiogram (for assessment of left ventricular end-diastolic and end-systolic volumes,&#xD;
      left ventricular ejection fraction); MLHFQ&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    difficulties in recruiting patients&#xD;
  </why_stopped>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Right ventricular pacing percentage increase &gt; 50% or cardiovascular death or Heart failure decompensation or Crossover due to worsening heart failure.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of episodes of non-sustained and sustained ventricular tachycardia and ventricular fibrillation</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of ICD shock-delivery for ventricular fibrillation and sustained ventricular tachycardia</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction decrease &lt; 5% from baseline value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left Ventricular End-Systolic Volume decrease &lt;15% from baseline value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate variability increase (&gt; 10%) from baseline value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>reduction of at least one NYHA Class from baseline value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minnesota Living Heart Failure Questionnaire scores (&gt;5) from the baseline score.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right ventricular pacing percentage reduction (&gt; 10%) from baseline value</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite endpoint: number of cardiovascular death and hospitalization due to worsening heart failure.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Crossover rate due to worsening heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Heart Rate Control in ICD Patients With Heart Failure</condition>
  <arm_group>
    <arm_group_label>ivabradine plus beta-blocker(bisoprolol)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>beta-blocker (bisoprolol) titration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beta blocker Bisoprolol will be titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivabradine plus beta-blocker (bisoprolol)</intervention_name>
    <description>Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).</description>
    <arm_group_label>ivabradine plus beta-blocker(bisoprolol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>betablocker titration</intervention_name>
    <description>Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.</description>
    <arm_group_label>beta-blocker (bisoprolol) titration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age ≥ 18 years.&#xD;
&#xD;
        Patients with stable chronic heart failure implanted with mono-cameral or bicameral ICD&#xD;
        with a home monitoring remote control.&#xD;
&#xD;
        Moderate to severe left ventricular dysfunction (FE ≤ 40%).&#xD;
&#xD;
        Any cause of heart failure was allowed apart congenital heart disease.&#xD;
&#xD;
        Bicameral ICD programmed in DDD or AAI/DDD with AV interval &lt; 300 msec.&#xD;
&#xD;
        Rest ECG heart rate ≥70 bpm;&#xD;
&#xD;
        Sinus rhythm.&#xD;
&#xD;
        In therapy with low-dose of beta-blocker (bisoprolol 1,25-2,5 mg) and with the maximum dose&#xD;
        tolerated of angiotensin-converting enzyme inhibitor or blockade of angiotensin II&#xD;
        receptor, mineralocorticoid antagonist, antiplatelet and lipid-lowering therapy, unless&#xD;
        contraindicated.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Inability of providing informed consent;&#xD;
&#xD;
        Age &lt; 18 years.&#xD;
&#xD;
        State of pregnancy or lactation.&#xD;
&#xD;
        Recent (&lt;2 months) myocardial infarction;&#xD;
&#xD;
        Contraindications to beta-blockers and ivabradine;&#xD;
&#xD;
        Rest ECG heart rate &lt; 70 bpm;&#xD;
&#xD;
        No sinus rhythm.&#xD;
&#xD;
        Administration of non-dihydropyridinic calcium channels antagonists, digitalis, class I&#xD;
        antiarrhythmic drugs, strong inhibitors of cytochrome P450 3A4 at the time of enrollment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Polinico Casilino</name>
      <address>
        <city>Rome</city>
        <zip>00169</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Sharma AD, Rizo-Patron C, Hallstrom AP, O'Neill GP, Rothbart S, Martins JB, Roelke M, Steinberg JS, Greene HL; DAVID Investigators. Percent right ventricular pacing predicts outcomes in the DAVID trial. Heart Rhythm. 2005 Aug;2(8):830-4.</citation>
    <PMID>16051118</PMID>
  </reference>
  <reference>
    <citation>Smit MD, Van Dessel PF, Nieuwland W, Wiesfeld AC, Tan ES, Anthonio RL, Van Erven L, Van Veldhuisen DJ, Van Gelder IC. Right ventricular pacing and the risk of heart failure in implantable cardioverter-defibrillator patients. Heart Rhythm. 2006 Dec;3(12):1397-403. Epub 2006 Aug 10.</citation>
    <PMID>17161779</PMID>
  </reference>
  <reference>
    <citation>Borer JS, Le Heuzey JY. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor. Am J Ther. 2008 Sep-Oct;15(5):461-73. doi: 10.1097/MJT.0b013e3181758855. Review.</citation>
    <PMID>18806523</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 9, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <last_update_submitted>March 11, 2020</last_update_submitted>
  <last_update_submitted_qc>March 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinico Casilino ASL RMB</investigator_affiliation>
    <investigator_full_name>Leonardo Calò, MD</investigator_full_name>
    <investigator_title>MD, FESC</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bisoprolol</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

